MedInCell Shares Drop 3.72%, Falling Below Key Moving Averages
The Montpellier-based biotech company's stock significantly declined this Tuesday, moving against the trend of a CAC 40 that rose by 1.33% during the session. MedInCell fell by 3.72% to €22.24, after closing at €23.10 before the long Easter weekend. This decline is part of a challenging quarter for the stock, which has seen a decrease of more than 9% over three months.
In mid-morning trading, MedInCell is priced at €22.24, now below its 50-day moving average of €23.22 and its 200-day average of €23.52. This double dip below these medium and long-term benchmarks indicates a selling pressure that has been mounting over the past few weeks, with the stock having lost more than 9% since the beginning of January. However, the price remains above its 20-day moving average of €21.62, which acts as the first cushion.
The RSI indicator is positioned at 53, which is in the neutral zone, indicating neither overbought nor oversold conditions. The Bollinger Bands frame the price between an upper limit of €23.41 and a lower limit of €19.82: the stock is in the upper half of this channel. The technical support identified at €20.24 is the next threshold to watch if the decline continues, while resistance is found at €24.94.
Upcoming Financial Milestones
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Today's decline comes as the company, which specializes in long-duration injection technologies, approaches significant deadlines. The publication of the annual results for the fiscal year 2025-2026 is scheduled for June 16th, an event expected to provide greater visibility into the financial trajectory of the group. The general meeting will follow on September 10th, before the announcement of the results for the first half of 2026-2027 expected on December 8th.
The stock performance of MedInCell remains mixed depending on the time horizon considered: while the stock has increased by more than 66% over the past year, it has fallen by 9% over the last quarter. The volatility measured over a month is 14.46%, and the beta of 0.08 indicates a low correlation with general market movements. Among comparable pharmaceutical sector stocks, Sanofi is up 0.85% in today's session, while UCB has dropped 1.36%. MedInCell's decline thus appears more pronounced than the sector trend observed this morning on European markets.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
